China adds Ascentage's lisaftoclax to NRDL; olverembatinib coverage renewed after renegotiation
Ascentage Pharma says its Bcl-2 inhibitor lisaftoclax enters China's reimbursement list for the first time, while olverembatinib keeps its place after renegotiation.
Ascentage Pharma announced on 16 November 2026 that lisaftoclax, its Bcl-2 inhibitor, has been included in China's National Reimbursement Drug List (NRDL) for the first time. The listing covers adults with relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have already received therapy that included a BTK inhibitor.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Ascentage Pharma Group International ↗
Article written by VigiEye from the official source (Ascentage Pharma Group International). Claims are the company's own. AI-assisted; check the source before acting.